Drug Profile
Research programme: fatty acid synthase inhibitors - GlaxoSmithKline
Alternative Names: GSK 837149ALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Small molecules; Sulfonamides; Urea compounds
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 28 Aug 2011 Early research is ongoing in USA